A Study for Long-Term Follow-up of Patients with Multiple Sclerosis who Participated in Previous Study of Alemtuzumab


About this study

The purpose of this study is to evaluate the long-term safety, effectiveness, and patient reported quality of life outcomes of treatment with alemtuzumab for patients who have multiple sclerosis and participated in a previous study of alemtuzumab.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Completed at least 48 months of the Extension Study CAMMS03409
  • Signed written informed consent form

Exclusion Criteria

  • Is participating in another investigational interventional study
  • Not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Jonathan Carter, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer